Literature DB >> 18366322

Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer.

Antonio C Westphalen1, David A McKenna, John Kurhanewicz, Fergus V Coakley.   

Abstract

PURPOSE: To describe the practical technical aspects of magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) and to summarize the current and potential future status of MRI and MRSI in the localization, staging, treatment planning, and post-treatment follow-up of prostate cancer. TECHNIQUE: Published contemporary series of patients with prostate cancer evaluated by MRI and MRSI before or after radiation therapy were reviewed, with particular respect to the role of MRI and MRSI in treatment planning, outcome prediction, and detecting local recurrence.
RESULTS: Volumetric localization is of limited accuracy for tumors less than 0.5 cm(3). Staging by MRI, which is improved by the addition of MRSI, is of incremental prognostic significance in patients with moderate and high-risk tumors. The finding of more than 5 mm of extracapsular extension prior to radiation seems to be of particular negative prognostic significance, and the latter group may be candidates for more aggressive supplemental therapy. The use of MRI to assist radiation treatment planning has been shown to improve outcome. MRSI may be helpful in the detection of local recurrence after radiation.
CONCLUSIONS: Only MRI and MRSI allow combined structural and metabolic evaluation of prostate cancer location, aggressiveness, and stage. Combined MRI and MRSI provide clinically and therapeutically relevant information that may assist in planning and post-treatment monitoring in patients undergoing radiation therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18366322      PMCID: PMC2745629          DOI: 10.1089/end.2007.9822

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  64 in total

1.  The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer.

Authors:  M Debois; R Oyen; F Maes; G Verswijvel; G Gatti; H Bosmans; M Feron; E Bellon; G Kutcher; H Van Poppel; L Vanuytsel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

2.  Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes.

Authors:  F V Coakley; H Hricak; A E Wefer; J L Speight; J Kurhanewicz; M Roach
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

Review 3.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis.

Authors:  S Nag; W Bice; K DeWyngaert; B Prestidge; R Stock; Y Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

4.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.

Authors:  J Scheidler; H Hricak; D B Vigneron; K K Yu; D L Sokolov; L R Huang; C J Zaloudek; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

5.  Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; B Malkowicz; M Schnall; D Schultz; K Cote; J E Tomaszewski; A Wein
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

6.  Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study.

Authors:  V S Khoo; A R Padhani; S F Tanner; D J Finnigan; M O Leach; D P Dearnaley
Journal:  Br J Radiol       Date:  1999-06       Impact factor: 3.039

7.  Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity.

Authors:  C Menard; I C Smith; R L Somorjai; L Leboldus; R Patel; C Littman; S J Robertson; T Bezabeh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-06-01       Impact factor: 7.038

8.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging.

Authors:  Fergus V Coakley; John Kurhanewicz; Ying Lu; Kirk D Jones; Mark G Swanson; Silvia D Chang; Peter R Carroll; Hedvig Hricak
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

9.  Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.

Authors:  M Zaider; M J Zelefsky; E K Lee; K L Zakian; H I Amols; J Dyke; G Cohen; Y Hu; A K Endi; C Chui; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

10.  Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.

Authors:  Antonio C Westphalen; Fergus V Coakley; Aliya Qayyum; Mark Swanson; Jeffry P Simko; Ying Lu; Shoujun Zhao; Peter R Carroll; Benjamin M Yeh; John Kurhanewicz
Journal:  Radiology       Date:  2007-11-16       Impact factor: 11.105

View more
  7 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

Review 2.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

3.  Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.

Authors:  Antonio C Westphalen; Fergus V Coakley; John Kurhanewicz; Galen Reed; Zhen J Wang; Jeffry P Simko
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

4.  Challenges in clinical prostate cancer: role of imaging.

Authors:  Gary J Kelloff; Peter Choyke; Donald S Coffey
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

5.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

6.  Evaluation of intraoperative magnetic resonance imaging/ultrasound fusion optimization for low-dose-rate prostate brachytherapy.

Authors:  Stephen Abel; Paul Renz; Olivier Gayou; Jie Tang; E Day Werts; Mark Trombetta
Journal:  J Contemp Brachytherapy       Date:  2017-08-01

7.  Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: can we assess treatment response on imaging?

Authors:  Sandeep Hedgire; Aoife Kilcoyne; Alexey Tonyushkin; Yun Mao; Jennifer W Uyeda; Debra A Gervais; Mukesh G Harisinghani
Journal:  Br J Radiol       Date:  2018-09-21       Impact factor: 3.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.